Extracorporeal Membrane Oxygenation for Severe COVID-19 in Indian Scenario: A Single Centre Retrospective Study

Background:Initial reports from Wuhan (China) suggested poor outcomes for severe COVID-19 patients treated with Extracorporeal Membrane Oxygenation (ECMO). Extracorporeal Membrane Oxygenation (ELSO) interim 2019 guidelines also recommended using ECMO only when all conventional therapies are exhausted. However, later studies showed that delayed ECMO initiation may lead to longer ECMO runs, offsetting any benefit from resource conservation by delaying the initiation. Hence, this study was intended to analyze the socio-demographic characteristics, type of ECMO, and complications of its outcome in the Indian scenario.Materials and methods: Demographic and patient clinical outcome data of all the patients of severe ARDS due to COVID-19 being treated with ECMO from 1st June 2020 to 31st May 2021 at Medica Super-specialty Hospital (Kolkata, India), were retrospectively compiled and analyzed.Results: Total number of patients treated was 79 with 10% female representation. The mean age was 43 & PLUSMN; 3.2 years and the mean body mass index 37 & PLUSMN; 4.3. Fifty percent of the patient survived. The mean duration of the ECMO run was 17 & PLUSMN; 5.2 days. Sepsis (65%) was the commonest complication observed followed by acute kidney injury (39%).Conclusions:This study provides significant insight into the outcomes of patients of COVID-19 treated by ECMO in the Indian scenario. Mortality rates of COVID-19 patients on ECMO were comparable to the non-COVID-19 patients, although the ECMO run time was relatively longer. Our study concluded that ECMO should be considered as a treatment option in appropriate COVID-19 cases. However, if the capacity diminishes in a pandemic situation, ECMO consideration should be based on more stringent criteria.